Shopping Cart 0
Cart Subtotal
USD 0

Global Companion Diagnostics Market - Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018-2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Global Companion Diagnostics Market-Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018-2024

Overview: Companion diagnostics are molecular tests that provide essential information for the safety and effective use of the corresponding drug. These tests assist healthcare professionals to decide whether a specific treatment product benefits patient for curing disease, predict drug toxicities, off-target effects of treatment, and other adverse effects related to the drug. It is also used during clinical trials to guide treatment, which can improve therapy responses and treatment outcomes. Currently, there are over 20 approved or cleared companion diagnostic tests and most of the tests are for cancer treatments targeting mutation. According to the estimation of National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths were recorded in 2016. While in Europe, 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades. The trend of increasing incidence of cancer & infectious diseases is catching up even in developing countries due to increased adoption of the Western lifestyle, which is expected to fuel the growth of the companion diagnostics market in coming years.

The companion diagnostics market is booming due to increasing patient base for infectious diseases & cancer globally, high adoption of companion diagnostics, growing demand for companion diagnostics, and emerging applications of companion diagnostics. Low awareness & lack of professionals to conduct tests and unfavorable reimbursement scenario in developed & developing countries are few of the factors hampering the market growth to an extent.

Market Analysis: The Global Companion Diagnostics market is estimated to witness a CAGR of 19.6% during the forecast period 2018-2024. The market is analyzed based on four segments-technology, applications, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the companion diagnostics market growth followed by Europe, Asia Pacific, and Rest of the World.

Technology Analysis: The global companion diagnostics market, by technology, is segmented into polymerase chain reaction, immunohistochemistry, in-situ hybridization, next-generation sequencing, and others. Polymerase chain reaction occupied the largest share in 2017, and next-generation sequencing is expected to grow at a high CAGR in the coming years.

Application Analysis: The global companion diagnostics market, by application, is segmented into cancer, infectious disease, and others. The cancer application is further segmented into colorectal cancer, breast cancer, lung cancer, melanoma, and others. In 2017, cancer application occupied a significant market share and is expected to be the same during the forecast period due to increasing incidence of cancer, changing lifestyle, and growing

For instance, in February 2017, Roche announced the launch of Elecsys AMH Plus immunoassay, the first companion diagnostic to be approved for use in fertility. The key market players are receiving product approvals that are helping them to increase the market share. For instance, in June 2017, the US FDA granted approval to Thermo Fisher Scientific for NGS-based test known as the Oncomine Dx Target test, which instantaneously evaluates 23 genes clinically related to NSCLC.

Benefits: The report provides complete details about the usage and adoption rate of companion diagnostics products in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

 

READ MORE

Table Of Content

Scope

Table of Contents

1 INDUSTRY OUTLOOK 9

1.1 Industry overview 9

1.2 Total addressable market 9

1.3 Industry Trends 10

2 Report Outline 10

2.1 Report Scope 10

2.2 Report Summary 11

2.3 Research Methodology 12

2.4 Report Assumptions 12

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Importance of Companion diagnostics 13

3.3 Segmented Addressable Market (SAM) 13

3.4 Trends of the companion diagnostics market 14

3.5 Related Markets 15

3.5.1 Personalized medicine 15

3.5.2 Genetic testing Market 16

3.5.3 Point-Of-Care Diagnostics Market 16

4 Market Outlook 16

4.1 Overview 16

4.2 Regulatory Scenario 17

4.3 Market segmentation 18

4.4 PEST Analysis 18

4.5 Porter 5(Five) Forces 20

5 Market Characteristics 21

5.1 DRO-Global Companion Diagnostics Market Dynamics 21

5.1.1 Drivers 21

5.1.1.1 Growing incidence of cancer across the globe 21

5.1.1.2 Rising adoption of companion diagnostics tests 22

5.1.1.3 Growing demand of personalized medicine 23

5.1.2 Opportunities 23

5.1.2.1 Emerging applications of companion diagnostics 23

5.1.2.2 Growing demand for next-generation sequencing 23

5.1.3 Restraints 24

5.1.3.1 Uncertain reimbursement scenario in developed and developing countries 24

5.1.3.2 Lack of professionals to perform the test 25

6 Technology: Market Size and Analysis 27

6.1 Overview 27

6.2 Polymerase Chain Reaction 27

6.3 In Situ Hybridization 28

6.4 Immunohistochemistry 29

6.5 Next-Generation Sequencing 29

6.6 Others 30

7 Application: Market Size and Analysis 31

7.1 Overview 31

7.2 Cancer 31

7.2.1 Lung cancer 32

7.2.2 Breast cancer 33

7.2.3 Colorectal cancer 33

7.2.4 Melanoma 34

7.2.5 Others 34

7.3 Infectious disease 35

7.4 Others 35

8 End Users: Market Size and Analysis 36

8.1 Overview 36

8.2 Pharma and biopharma companies 36

8.3 Reference Laboratories 37

8.4 Others 37

9 Regions: Market Size and Analysis 37

9.1 Overview 38

9.2 North America 39

9.2.1 Overview 39

9.2.2 US 40

9.2.3 Canada 40

9.3 Europe 40

9.3.1 Overview 40

9.3.2 UK 41

9.3.3 Germany 42

9.3.4 France 42

9.3.5 Spain 42

9.4 APAC 42

9.4.1 Overview 42

9.4.2 India 43

9.4.3 China 44

9.5 Rest of the World 44

10 Competitive Landscape 46

10.1 Overview 46

11 Vendor Profiles 50

11.1 F.Hoffmann-La Roche Ltd 50

11.1.1 Overview 50

11.1.2 Business Unit 53

11.1.3 Geographic Presence 54

11.1.4 Business Focus 55

11.1.5 SWOT Analysis 55

11.1.6 Business Strategy 56

11.2 Qiagen N.V. 58

11.2.1 Overview 58

11.2.2 Geographic Presence 62

11.2.3 Business Focus 62

11.2.4 SWOT Analysis 63

11.2.5 Business Strategies 63

11.3 Abbott Laboratories 65

11.3.1 Overview 65

11.3.2 Business Unit 68

11.3.3 Geographic Presence 68

11.3.4 Business Focus 69

11.3.5 SWOT Analysis 70

11.3.6 Business Strategy 70

11.4 Myriad Genetics Inc. 72

11.4.1 Overview 72

11.4.2 Business Unit 74

11.4.3 Business Focus 75

11.4.4 SWOT Analysis 76

11.4.5 Business Strategy 76

11.5 Agilent Technologies Inc. 78

11.5.1 Overview 78

11.5.2 Business Units 81

11.5.3 Geographic Presence 82

11.5.4 Business Focus 83

11.5.5 SWOT Analysis 83

11.5.6 Business Strategies 84

12 Companies to Watch For 86

12.1 BioMerieux S.A. 86

12.1.1 Overview 86

12.1.2 BioMerieux S.A.: Recent Developments 86

12.2 Danaher Corporation (Leica Microsystems AG) 87

12.2.1 Overview 87

12.2.2 Danaher Corporation: Recent Developments 88

12.3 Resonance Health Limited 89

12.3.1 Overview 89

12.3.2 Resonance Health Limited: Recent Developments 89

12.4 Thermo Fisher Scientific 90

12.4.1 Overview 90

12.4.2 Thermo Fisher Scientific: Recent Developments 91

12.5 Genomic Health, Inc. 93

12.5.1 Overview 93

12.5.2 Genomic Health: Recent Developments 94

13 Annexure 96

13.1 Abbreviations 96

 


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL COMPANION DIAGNOSTICS MARKET 12

CHART 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE, 2017-2024 (USD MILLION) 15

CHART 3 PEST ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET 18

CHART 4 PORTER 5 FORCES ON GLOBAL COMPANION DIAGNOSTICS MARKET 20

CHART 5 DRO-IMPACT ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET 25

CHART 6 KEY STAKEHOLDERS 26

CHART 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY SEGMENTATION, 2017 (%) 27

CHART 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 31

CHART 9 GLOBAL COMPANION DIAGNOSTIC MARKET BY CANCER APPLICATION SEGMENTATION, 2017 (%) 32

CHART 10 GLOBAL COMPANION DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%) 36

CHART 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 38

CHART 12 COMPANION DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 39

CHART 13 COMPANION DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 41

CHART 14 COMPANION DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017-2024 (USD MILLION) 43

CHART 15 COMPANION DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 45

CHART 20 QIAGEN N.V.: OVERVIEW SNAPSHOT 61

CHART 21 QIAGEN N.V.: GEOGRAPHICAL PRESENCE 62

CHART 22 QIAGEN N.V.: SWOT ANALYSIS 63

CHART 23 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT 67

CHART 24 ABBOTT LABORATORIES.: BUSINESS UNITS 68

CHART 25 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 68

CHART 26 ABBOTT LABORATORIES.: SWOT ANALYSIS 70

CHART 27 MYRIAD GENETICS: OVERVIEW SNAPSHOT 73

CHART 28 MYRIAD GENETICS: BUSINESS UNITS 74

CHART 29 MYRIAD GENETICS: SWOT ANALYSIS 76

CHART 30 AGILENT TECHNOLOGIES INC.: OVERVIEW SNAPSHOT 80

CHART 31 AGILENT TECHNOLOGIES INC.: BUSINESS UNITS 81

CHART 32 AGILENT TECHNOLOGIES: GEOGRAPHICAL PRESENCE 82

CHART 33 AGILENT TECHNOLOGIES INC.: SWOT ANALYSIS 83

 


List Of Table

Tables

 

TABLE 1 REGULATORY SCENARIO 17

TABLE 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 38

TABLE 3 GLOBAL COMPANION DIAGNOSTICS MARKET BY VENDOR RANKING, 2017 48

TABLE 4 OTHER PROMINENT VENDORS OF COMPANION DIAGNOSTICS MARKET 49

TABLE 5 F. HOFFMANN-LA ROCHE: OFFERINGS 50

TABLE 6 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 51

TABLE 7 QIAGEN N.V.: PRODUCT OFFERINGS 58

TABLE 8 QIAGEN N.V.: RECENT DEVELOPMENTS 58

TABLE 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS 65

TABLE 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 65

TABLE 11 MYRIAD GENETICS: PRODUCT DESCRIPTION 72

TABLE 12 MYRIAD GENETICS: RECENT DEVELOPMENTS 72

TABLE 13 AGILENT TECHNOLOGIES INC.: PRODUCT OFFERINGS 78

TABLE 14 AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS 79

TABLE 15 BIOMERIEUX S.A.: SNAPSHOT 86

TABLE 16 DANAHER CORPORATION: SNAPSHOT 87

TABLE 17 RESONANCE HEALTH LIMITED: SNAPSHOT 89

TABLE 18 THERMO FISHER SCIENTIFIC: SNAPSHOT 91

TABLE 19 GENOMIC HEALTH: SNAPSHOT 94

 

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

F. Hoffmann-La Roche Ltd, Qiagen N.V., Abbott Laboratories, Myriad Genetics, Agilent Technologies, Inc., BioMerieux S.A., Danaher Corporation (Leica Microsystems AG), Resonance Health Limted, Thermo Fisher Scientific, Inc., Genomic Health, Inc

Global Companion Diagnostics Market-Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018-2024

Overview: Companion diagnostics are molecular tests that provide essential information for the safety and effective use of the corresponding drug. These tests assist healthcare professionals to decide whether a specific treatment product benefits patient for curing disease, predict drug toxicities, off-target effects of treatment, and other adverse effects related to the drug. It is also used during clinical trials to guide treatment, which can improve therapy responses and treatment outcomes. Currently, there are over 20 approved or cleared companion diagnostic tests and most of the tests are for cancer treatments targeting mutation. According to the estimation of National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths were recorded in 2016. While in Europe, 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades. The trend of increasing incidence of cancer & infectious diseases is catching up even in developing countries due to increased adoption of the Western lifestyle, which is expected to fuel the growth of the companion diagnostics market in coming years.

The companion diagnostics market is booming due to increasing patient base for infectious diseases & cancer globally, high adoption of companion diagnostics, growing demand for companion diagnostics, and emerging applications of companion diagnostics. Low awareness & lack of professionals to conduct tests and unfavorable reimbursement scenario in developed & developing countries are few of the factors hampering the market growth to an extent.

Market Analysis: The Global Companion Diagnostics market is estimated to witness a CAGR of 19.6% during the forecast period 2018-2024. The market is analyzed based on four segments-technology, applications, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the companion diagnostics market growth followed by Europe, Asia Pacific, and Rest of the World.

Technology Analysis: The global companion diagnostics market, by technology, is segmented into polymerase chain reaction, immunohistochemistry, in-situ hybridization, next-generation sequencing, and others. Polymerase chain reaction occupied the largest share in 2017, and next-generation sequencing is expected to grow at a high CAGR in the coming years.

Application Analysis: The global companion diagnostics market, by application, is segmented into cancer, infectious disease, and others. The cancer application is further segmented into colorectal cancer, breast cancer, lung cancer, melanoma, and others. In 2017, cancer application occupied a significant market share and is expected to be the same during the forecast period due to increasing incidence of cancer, changing lifestyle, and growing

For instance, in February 2017, Roche announced the launch of Elecsys AMH Plus immunoassay, the first companion diagnostic to be approved for use in fertility. The key market players are receiving product approvals that are helping them to increase the market share. For instance, in June 2017, the US FDA granted approval to Thermo Fisher Scientific for NGS-based test known as the Oncomine Dx Target test, which instantaneously evaluates 23 genes clinically related to NSCLC.

Benefits: The report provides complete details about the usage and adoption rate of companion diagnostics products in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player's initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

 

 

READ MORE

Scope

Table of Contents

1 INDUSTRY OUTLOOK 9

1.1 Industry overview 9

1.2 Total addressable market 9

1.3 Industry Trends 10

2 Report Outline 10

2.1 Report Scope 10

2.2 Report Summary 11

2.3 Research Methodology 12

2.4 Report Assumptions 12

3 Market Snapshot 13

3.1 Market Definition-Infoholic Research 13

3.2 Importance of Companion diagnostics 13

3.3 Segmented Addressable Market (SAM) 13

3.4 Trends of the companion diagnostics market 14

3.5 Related Markets 15

3.5.1 Personalized medicine 15

3.5.2 Genetic testing Market 16

3.5.3 Point-Of-Care Diagnostics Market 16

4 Market Outlook 16

4.1 Overview 16

4.2 Regulatory Scenario 17

4.3 Market segmentation 18

4.4 PEST Analysis 18

4.5 Porter 5(Five) Forces 20

5 Market Characteristics 21

5.1 DRO-Global Companion Diagnostics Market Dynamics 21

5.1.1 Drivers 21

5.1.1.1 Growing incidence of cancer across the globe 21

5.1.1.2 Rising adoption of companion diagnostics tests 22

5.1.1.3 Growing demand of personalized medicine 23

5.1.2 Opportunities 23

5.1.2.1 Emerging applications of companion diagnostics 23

5.1.2.2 Growing demand for next-generation sequencing 23

5.1.3 Restraints 24

5.1.3.1 Uncertain reimbursement scenario in developed and developing countries 24

5.1.3.2 Lack of professionals to perform the test 25

6 Technology: Market Size and Analysis 27

6.1 Overview 27

6.2 Polymerase Chain Reaction 27

6.3 In Situ Hybridization 28

6.4 Immunohistochemistry 29

6.5 Next-Generation Sequencing 29

6.6 Others 30

7 Application: Market Size and Analysis 31

7.1 Overview 31

7.2 Cancer 31

7.2.1 Lung cancer 32

7.2.2 Breast cancer 33

7.2.3 Colorectal cancer 33

7.2.4 Melanoma 34

7.2.5 Others 34

7.3 Infectious disease 35

7.4 Others 35

8 End Users: Market Size and Analysis 36

8.1 Overview 36

8.2 Pharma and biopharma companies 36

8.3 Reference Laboratories 37

8.4 Others 37

9 Regions: Market Size and Analysis 37

9.1 Overview 38

9.2 North America 39

9.2.1 Overview 39

9.2.2 US 40

9.2.3 Canada 40

9.3 Europe 40

9.3.1 Overview 40

9.3.2 UK 41

9.3.3 Germany 42

9.3.4 France 42

9.3.5 Spain 42

9.4 APAC 42

9.4.1 Overview 42

9.4.2 India 43

9.4.3 China 44

9.5 Rest of the World 44

10 Competitive Landscape 46

10.1 Overview 46

11 Vendor Profiles 50

11.1 F.Hoffmann-La Roche Ltd 50

11.1.1 Overview 50

11.1.2 Business Unit 53

11.1.3 Geographic Presence 54

11.1.4 Business Focus 55

11.1.5 SWOT Analysis 55

11.1.6 Business Strategy 56

11.2 Qiagen N.V. 58

11.2.1 Overview 58

11.2.2 Geographic Presence 62

11.2.3 Business Focus 62

11.2.4 SWOT Analysis 63

11.2.5 Business Strategies 63

11.3 Abbott Laboratories 65

11.3.1 Overview 65

11.3.2 Business Unit 68

11.3.3 Geographic Presence 68

11.3.4 Business Focus 69

11.3.5 SWOT Analysis 70

11.3.6 Business Strategy 70

11.4 Myriad Genetics Inc. 72

11.4.1 Overview 72

11.4.2 Business Unit 74

11.4.3 Business Focus 75

11.4.4 SWOT Analysis 76

11.4.5 Business Strategy 76

11.5 Agilent Technologies Inc. 78

11.5.1 Overview 78

11.5.2 Business Units 81

11.5.3 Geographic Presence 82

11.5.4 Business Focus 83

11.5.5 SWOT Analysis 83

11.5.6 Business Strategies 84

12 Companies to Watch For 86

12.1 BioMerieux S.A. 86

12.1.1 Overview 86

12.1.2 BioMerieux S.A.: Recent Developments 86

12.2 Danaher Corporation (Leica Microsystems AG) 87

12.2.1 Overview 87

12.2.2 Danaher Corporation: Recent Developments 88

12.3 Resonance Health Limited 89

12.3.1 Overview 89

12.3.2 Resonance Health Limited: Recent Developments 89

12.4 Thermo Fisher Scientific 90

12.4.1 Overview 90

12.4.2 Thermo Fisher Scientific: Recent Developments 91

12.5 Genomic Health, Inc. 93

12.5.1 Overview 93

12.5.2 Genomic Health: Recent Developments 94

13 Annexure 96

13.1 Abbreviations 96

 


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL COMPANION DIAGNOSTICS MARKET 12

CHART 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE, 2017-2024 (USD MILLION) 15

CHART 3 PEST ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET 18

CHART 4 PORTER 5 FORCES ON GLOBAL COMPANION DIAGNOSTICS MARKET 20

CHART 5 DRO-IMPACT ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET 25

CHART 6 KEY STAKEHOLDERS 26

CHART 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY SEGMENTATION, 2017 (%) 27

CHART 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 31

CHART 9 GLOBAL COMPANION DIAGNOSTIC MARKET BY CANCER APPLICATION SEGMENTATION, 2017 (%) 32

CHART 10 GLOBAL COMPANION DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%) 36

CHART 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 38

CHART 12 COMPANION DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 39

CHART 13 COMPANION DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 41

CHART 14 COMPANION DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017-2024 (USD MILLION) 43

CHART 15 COMPANION DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 45

CHART 20 QIAGEN N.V.: OVERVIEW SNAPSHOT 61

CHART 21 QIAGEN N.V.: GEOGRAPHICAL PRESENCE 62

CHART 22 QIAGEN N.V.: SWOT ANALYSIS 63

CHART 23 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT 67

CHART 24 ABBOTT LABORATORIES.: BUSINESS UNITS 68

CHART 25 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 68

CHART 26 ABBOTT LABORATORIES.: SWOT ANALYSIS 70

CHART 27 MYRIAD GENETICS: OVERVIEW SNAPSHOT 73

CHART 28 MYRIAD GENETICS: BUSINESS UNITS 74

CHART 29 MYRIAD GENETICS: SWOT ANALYSIS 76

CHART 30 AGILENT TECHNOLOGIES INC.: OVERVIEW SNAPSHOT 80

CHART 31 AGILENT TECHNOLOGIES INC.: BUSINESS UNITS 81

CHART 32 AGILENT TECHNOLOGIES: GEOGRAPHICAL PRESENCE 82

CHART 33 AGILENT TECHNOLOGIES INC.: SWOT ANALYSIS 83

 


List Of Table

Tables

 

TABLE 1 REGULATORY SCENARIO 17

TABLE 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 38

TABLE 3 GLOBAL COMPANION DIAGNOSTICS MARKET BY VENDOR RANKING, 2017 48

TABLE 4 OTHER PROMINENT VENDORS OF COMPANION DIAGNOSTICS MARKET 49

TABLE 5 F. HOFFMANN-LA ROCHE: OFFERINGS 50

TABLE 6 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 51

TABLE 7 QIAGEN N.V.: PRODUCT OFFERINGS 58

TABLE 8 QIAGEN N.V.: RECENT DEVELOPMENTS 58

TABLE 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS 65

TABLE 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 65

TABLE 11 MYRIAD GENETICS: PRODUCT DESCRIPTION 72

TABLE 12 MYRIAD GENETICS: RECENT DEVELOPMENTS 72

TABLE 13 AGILENT TECHNOLOGIES INC.: PRODUCT OFFERINGS 78

TABLE 14 AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS 79

TABLE 15 BIOMERIEUX S.A.: SNAPSHOT 86

TABLE 16 DANAHER CORPORATION: SNAPSHOT 87

TABLE 17 RESONANCE HEALTH LIMITED: SNAPSHOT 89

TABLE 18 THERMO FISHER SCIENTIFIC: SNAPSHOT 91

TABLE 19 GENOMIC HEALTH: SNAPSHOT 94

 

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

F. Hoffmann-La Roche Ltd, Qiagen N.V., Abbott Laboratories, Myriad Genetics, Agilent Technologies, Inc., BioMerieux S.A., Danaher Corporation (Leica Microsystems AG), Resonance Health Limted, Thermo Fisher Scientific, Inc., Genomic Health, Inc